Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab with R-DHAOx salvage, ASCT, and consolidation for relapsed or refractory aggressive B-cell lymphoma
ACTRN12623000620628Phase 2Terminated
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and transformed B-cell lymphoma, sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Event-free survival. Started May 2024; status: terminated.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomatransformed B-cell lymphoma
Beyond the preview
Go deeper on ACTRN12623000620628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000620628.